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Abstract 
Objectives: Smoking is the leading cause of lung cancer. However, several studies have suggested 
other factors such as alcohol consumption could also play a role through polymorphisms 
associated with alcohol metabolism. We investigated the association between alcohol 
consumption and lung cancer according to the Ile349Val polymorphism in the alcohol 
dehydrogenase 3 ADH3 gene. 
Methods: We carried out a hospital-based case-control study, a total of 402 incident cases of lung 
cancer and 383 controls were genotyped for the Ile349Val polymorphism by polymerase chain 
reaction combined with restriction fragment length polymorphism. Alcohol consumption and 
other variables were measured using questionnaires in personal interviews. We used multiple 
logistic regressions to estimate adjusted odd ratios using and 95% confidence intervals. 
Results: In multivariate analysis, an increased risk of lung cancer was observed for the highest 
category of alcohol consumption (≥30 g/day), although it does not reach statistical significance 
(OR=1.60, 95% CI: 0.91–2.83). Besides, an increased risk of lung cancer was observed in the 
highest category of alcohol consumption for the Ile/Val genotype compared with the Ile/Ile 
genotype (OR=2.35, 95% CI: 1.04–5.33). 
Conclusions: This study suggests that beyond smoking consumption, a high consumption of 
alcohol might increase the risk of lung cancer. No clear association was found between alcohol 
consumption and lung cancer according to the Ile349Val polymorphism in ADH3 gene. 
Key words: Alcohol, Lung Cancer, Polymorphism, Acetaldehyde 
Introduction 
Lung cancer was the most common form of 
cancer worldwide in 2012, with approximately 1.82 
million incident cases and 1.59 million deaths due to 
lung cancer [1]. In Spain alone, lung cancer caused 
21,487 deaths [2]. 
Approximately 80–90% of lung cancer cases are 
related to smoking [3]. However, other factors such as 
genetic susceptibility, diet, and alcohol consumption 
may play a role in the individual variability. In fact, 
worldwide around 5.5% of all cancer cases and 5.8% 
of total cancer deaths were attributable to alcohol 
consumption [4]. Alcohol consumption is a known 
risk factor for several cancer sites such as the oral 
cavity, pharynx, larynx, esophagus, liver, colorectal 
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and female breast, although its role in lung cancer risk 
is still controversial [5-7]. In 1988, the International 
Agency for Research on Cancer concluded that “there 
are enough evidences that alcoholic beverages are 
carcinogenic in humans” [8]. Alcohol might act as a 
carcinogenic agent by acetaldehyde, first metabolite of 
alcohol oxidation, classified as carcinogenic in 
humans [9], and by altering single nucleotide 
polymorphisms in genes that are involved with 
alcohol metabolism or DNA damage repair. 
Differences in individual lung cancer susceptibility 
may thus be the result of varying acetaldehyde 
exposure owing to genetic variants in the alcohol 
metabolism pathways. 
Alcohol dehydrogenases (ADHs) are enzymes 
that oxidize ethanol to acetaldehyde, and seven ADHs 
have been identified in humans [10]. One of the 
functionally important polymorphic sites for ADH3 is 
Ile349Val, which causes an amino acid change from 
isoleucine (Ile) to valine (Val). Compared with the 
wild-type allele (349Ile), the variant allele (349Val) 
shows decreased ethanol oxidation by about 2.5-fold 
[11]. Therefore, the 349Ile allele produces 
acetaldehyde (a well-known carcinogenic agent) at 
higher rates, thus increasing exposure time to the 
carcinogenic effects of acetaldehyde. Individuals who 
possess the more active variant (349Ile) then have a 
greater risk of developing alcohol-related cancer 
[12-14].  
In Western populations, epidemiological studies 
on the association between the Ile349Val 
polymorphism in the ADH3 gene and cancer risk have 
shown inconsistent results [15-20]. Only two studies 
have examined the Ile349Val polymorphism in the 
ADH3 gene and the risk of developing lung cancer, 
but no association was found [7, 21]. 
We used data from the CAPUA (Cáncer de 
Pulmón en Asturias [Lung Cancer in Asturias], Spain) 
study, a hospital-based case-control study of lung 
cancer carried out in four hospitals in the Asturias 
region of Spain [22-28], to examine the effect of 
alcohol consumption on lung cancer risk according to 
the Ile349Val polymorphism in the ADH3 gene. 
Material and Methods 
Details of the CAPUA hospital-based 
case-control study have been previously described 
[22-28]. Briefly, a total of 877 incident lung cancer 
cases aged 30-85 years were recruited and 
interviewed in four main hospitals of Asturias in 
northern Spain from October 2000 to December 2010. 
Patients with primary cancer other than lung cancer in 
the last 5 years were excluded. All cases were newly 
diagnosed, previously untreated, and histologically 
confirmed with the exception of those with advanced 
stage IV disease for whom surgery is not 
appropriated, and therefore did not have histological 
confirmation. The diagnosis of such few cases was 
confirmed by the oncologist and they were defined as 
“Clinical Diagnosis”. A total of 840 controls were 
selected from the same hospitals among patients with 
unrelated diseases. Controls were individually 
matched to the cases in terms of sex, age (± 5 years), 
and hospital. The main disease diagnoses of the 
control series were as follows: 41.1% inguinal and 
abdominal hernias (ICD [International Classification 
of Diseases]-10: K40–K46); 32.5% injuries (ICD-10: 
S00–S99); 8.8% appendicitis (ICD-10: K35); and 13.3% 
intestinal obstructions (ICD-10: K56, K57, K60). The 
study was approved by the regional ethical committee 
of Asturias, and written consent was obtained from 
each participant. In 2010 the CAPUA Study was 
included in the ILCCO (International Lung Cancer 
Consortium, http://ilcco.iarc.fr) and SYNERGY 
group (http://SYNERGY.iarc.fr) from the 
International Agency for Research on Cancer [29, 30]. 
All 877 cases and 840 controls were Caucasian. 
Blood or buccal cell samples were obtained from 872 
(99.43%) cases and 825 (98.21%) controls. After 
excluding samples because of problems in DNA 
extraction or difficulties in genotyping mainly 
because of poor quality DNA, a total of 402 cases and 
383 controls were finally genotyped for the Ile349Val 
polymorphism in the ADH3 gene, and included in 
final analysis of this study. 
Data collection 
Information about known or potential lung 
cancer risk factors was personally collected by trained 
interviewers using computer-aided structured 
questionnaires during the first admission to hospital 
for diagnosis. The questionnaires collected 
information from the participants about age, sex, 
sociodemographic characteristics, tobacco history, 
diet (including alcohol consumption), occupation, and 
personal and family (first-degree relatives) history of 
cancer.  
Alcohol consumption and dietary intake were 
evaluated using a semi-quantitative food frequency 
questionnaire (FFQ) completed at an interview. The 
FFQ was an adapted version of the questionnaire by 
Willet et al. [31] and validated in an adult Spanish 
population [32-34]. The subjects were asked to report 
how often, on average, they had consumed 127 food 
items over the previous 5 years. Serving sizes were 
specified for each food item. The questionnaire 
offered nine options for the frequency of consumption 
for each food, ranging from never or less than once a 
month to six or more times per day. Nutrient values 
for each food in the questionnaire were obtained from 
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the food composition tables of the US Department of 
Agriculture and other Spanish sources [35, 36]. 
Energy intake in kcals/day was estimated for each 
participant. Vegetable and fruit intakes in grams per 
day were derived from the FFQ by summing the items 
of these groups. The reproducibility and validity of 
this FFQ is comparable to other widely used FFQs [31, 
37-40]. The average of correlation coefficients between 
nutrient intakes estimated using prospectively 
collected diet records and those estimated with the 
FFQ were 0.47 for validity and 0.40 for reproducibility 
[41]. This FFQ also showed satisfactory biochemical 
validity compared with plasma levels of carotenoids 
and vitamin C [33, 34]. Alcohol consumption and 
dietary intake were available on 297 cases and 292 
controls among the study participants. 
To measure total alcohol intake, the FFQ 
evaluated the following types of alcoholic drinks: red 
wine (125 mL), white wine (125 mL), beer (200 mL), 
sherry (50 mL), hard cider (125mL), sweet spirits (30 
mL), and brandy, gin, rum, whiskey, and vodka (40 
mL). The total alcohol intake in grams per day was 
obtained by summing the intake of alcoholic drinks 
and was grouped into four categories based on 
non-drinkers and tertiles of energy-adjusted intake of 
alcohol among controls. The energy-adjusted intake 
was computed using the residual method, in which 
each nutrient was regressed on total calories, and the 
population mean was then added back to the 
calculated residuals [31]. We excluded subjects with 
extreme values for mean daily energy intake (<500 
and >3500 kcal/day for women, <800 and >4000 
kcal/day for men) which indicate misreporting [40]. 
Study subjects were defined as never-smokers if 
they had smoked less than 100 cigarettes in their 
lifetime; under other conditions, they were defined as 
ever-smokers. Ever-smokers were additionally 
classified as current smokers if they had smoked at 
least one cigarette per day along the previous 6 
months or longer. Participants who had smoked 
regularly in the past but had stopped smoking at least 
1 year before they were interviewed were defined as 
former smokers; finally, individuals who had stopped 
smoking less than 1 year before the interview were 
defined as current smokers. Ever-smokers were asked 
about the duration (years) that they had smoked at 
least one cigarette a day and how many cigarettes 
they consumed on average per day. Besides, smoking 
was characterized in terms of pack-years (PY), which 
is defined as the number of packs of cigarettes 
smoked per day times the number of smoking years. 
Subjects were categorized as light (<36 PY) or heavy 
(≥36 PY) smokers based on mean cumulative tobacco 
consumption in the control group. 
Genotype determination 
Polymerase chain reaction (PCR) combined with 
restriction fragment length polymorphism was used 
to determine the ADH3 genotypes. Genomic DNA 
was extracted from peripheral blood samples or 
exfoliated buccal cells, as previously described [42]. 
For quality control, genotyping was repeated 
randomly in at least 5% of the samples, and two of the 
authors independently reviewed all the results. A 
quality control of 50 blood and mouthwash samples 
from the same participants was used to confirm the 
reliability of the genotyping results using the 
mouthwash samples. No differences were found in 
either of the quality controls. PCR reactions were 
performed in a total volume of 10 μL containing 20 ng 
of genomic DNA, 0.25 mM of deoxyribonucleotide 
triphosphate (Ecogen, Biologia Molecular S.L., 
Madrid, Spain), 0.2 units of Taq polymerase (Biotools, 
Inc., Madrid, Spain), and 2.5 pmol of each primer in 1 
× PCR buffer (Sigma-Aldrich Co., Madrid, Spain). The 
primers used for the amplification of ADH3 were (F) 
CAG TTA TAG CAG TCT GGA ATG CA and (R) 
CCG CTA CTG TAG AAT ACA AAG CA, and the 
PCR conditions were 30 cycles of 94°C for 30 s, 68°C 
for 30 s, and 72°C for 1 min. The reverse primer was 
designed to introduce a recognition site for the 
restriction enzyme SspI (Quimigen S.L., Madrid, Spain) 
by replacing an A with a G. A 5-μL aliquot of each 
PCR product was digested overnight at 37°C with 0.4 
units of SspI. The products were separated on agarose 
(CONDA Laboratories, Madrid, Spain) gels and 
stained with ethidium bromide (Merck KGaA, 
Madrid, Spain). To verify that the data obtained by 
restriction fragment length polymorphism were 
coincident with the allele sequence, representative 
fragments were sequenced (data not shown).  
Statistical analysis 
Tests for Hardy–Weinberg equilibrium among 
controls were conducted using observed genotype 
frequencies and a chi-square test with one degree of 
freedom. Univariate analysis was first performed to 
compare the distribution of age and sex and the 
frequencies of alleles and genotypes. The differences 
in the distribution between cases and controls were 
tested using the chi-square test for categorical 
variables and the t test for continuous variables. 
Crude odd ratios (ORs) and confidence intervals 
were calculated using Wolf's method [43]. 
Multivariate unconditional logistic regression 
analysis with adjustment for age, sex, and cigarette 
smoking in PYs was performed to calculate adjusted 
ORs and 95% confidence intervals (CIs). The models 
were made based on the variables with a level of 
significance of p<0.2 in the univariate analysis while 
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those with a level of significance of p<0.1 were 
maintained in the model as part of the likelihood ratio 
test. Variables were included in the final models if 
they modified the coefficients more than 10%. All 
statistical analyses were conducted using Stata 12.1 
software (Stata Corporation, College Station, TX, 
USA). 
Results 
 Table 1 shows the distribution of the main 
characteristics of cases and controls. Cases showed a 
markedly higher consumption of tobacco smoking 
than controls (61.93 vs. 35.35 mean of PY), higher 
mean daily energy (2434.49 vs. 2286.65 kcals/day) and 
lower vegetable intake (122.78 vs. 152.21 g/day). 
Squamous cell carcinoma was the main histological 
type of lung cancer (39.8%) and adenocarcinoma the 
second (28.1%) in cases. 
 
Table 1: Characteristics of lung cancer cases and control patients 
in CAPUA study. 
Variable Cases (402) 
n (%) 
Controls (383) 
n (%) 
p-valuea 
Gender    
 Male 354 (88.06) 332 (86.68)  
 Female  48 (11.94) 51 (13.32) 0.562 
Age (years), mean (SD) 65.77 (10.48) 63.15 (11.50) 0.001 
Pack-years (PY), mean (SD) 61.93 (35.34) 35.35 (30.38) <0.001 
 Never  29 (7.21) 106 (27.68) <0.001 
 <36  75 (18.66) 165 (43.08) 
  ≥36  298 (74.13)  112 (29.24)  
Smoking status    
 Never 29 (7.21) 106 (27.68)  
 Ever 373 (92.79) 277 (72.32) <0.001 
 Former 188 (47.00) 159 (41.95)  
 Current 182 (45.50) 114 (30.08) <0.001 
Alcohol consumption (g/day)b, 
mean (SD) 
30.40 (50.89) 23.69 (38.47) 0.072 
 Non-drinker (<0.1) 65 (21.89) 57 (19.59)  
 0.1-9.9 67 (22.56) 91 (31.27)  
 10-29.9  76 (25.59) 76 (25.77)  
 ≥30  89 (29.97) 68 (23.37) 0.074 
Caloriesb, mean (SD) 2434.49 
(918.76) 
2286.65 
(695.84) 
0.028 
Vegetable intake (g/day)b, mean 
(SD) 
122.78 (99.05) 152.21 (133.02) 0.002 
Fruit intake (g/day)b, mean (SD) 260.63 (197.70) 248.95 (213.35) 0.492 
Family history of cancer    
 No 219 (57.03) 232 (61.87)  
 Other cancer 128 (33.33) 119 (31.73)  
 Lung cancer 37 (9.64) 24 (6.40) 0.186 
 Missing values 18 8  
Histological type    
 Squamous cell 
carcinoma 
160 (39.80)   
 Adenocarcinoma 113 (28.11)   
 Small cell carcinoma 77 (19.15)   
 Large cell carcinoma 11 (2.74)   
 Non-differentiated 31 (7.71)   
 Othersc 4 (1.00)   
 Clinical diagnosis 6 (1.49)   
a Chi-squared test (categorical variables), t- test (continuous variables). 
b Available on 297 (73.9%) cases and 292 (76.2%) controls. 
c Other histological types included: 1 Stage I Non-Small Cell Carcinoma; 1 Stage I 
nontypeable; 1 Little differentiated adenosquamous; and 1 Indicative of sarcoma. 
 
We estimated the frequency of Ile349Val 
polymorphism in the ADH3 gene in lung cancer 
patients and controls to evaluate its association with 
the risk of lung cancer. The genotype distribution for 
the single nucleotide polymorphism studied was 
consistent with the Hardy–Weinberg equilibrium. The 
proportion of the ADH3 349Val allele and the Val/Val 
genotype in ADH3 was similar among cases and 
controls (Table 2). No association was found between 
the ADH3 Ile349Val polymorphism and lung cancer 
risk; compared with the wild genotype Ile/Ile, the 
adjusted ORs for Val/Val genotype and Val-carriers 
were 0.95 (95% CI, 0.52–1.75) and 0.84 (95% CI, 
0.57–1.24), respectively (Table 2). 
 
Table 2: Genotype distribution of ADH3 Ile349Val 
polymorphism and adjusted ORs for lung cancer in CAPUA Study 
ADH3 genotype Cases 
(n=402) 
n (%) 
Controls 
(n=383) 
n (%) 
p-valuea Crude 
OR 
Adjusted 
OR 
[95%CI]b 
Ile/Ile 157 (39.05) 141 (36.81)  Reference Reference 
Ile/Val 194 (48.26) 196 (51.17) 0.518 0.89 0.82 
[0.55–1.22] 
Val/Val 51 (12.69) 46 (12.01)  1.00 0.95 
[0.52–1.75] 
Val-carriers 245 (60.95) 242 (60.95)  0.91 0.84 
[0.57–1.24] 
Frequency of 
Val allele 
0.37 0.38    
a Chi-squared test. 
bAdjusted for age, gender, cigarette smoking in pack years (continuous), alcohol 
consumption (g/day), energy intake (calories). 
 
 
Table 3 presents the association between alcohol 
consumption and lung cancer risk. An increased risk 
of lung cancer was observed in the highest category of 
alcohol consumption (≥30 g/day), although it was not 
statistically significant (OR=1.60, 95% CI, 0.91–2.83) 
(Table 3). 
 
Table 3: Alcohol consumption and lung cancer risk by histology 
type in CAPUA Study 
Alcohol 
consumption 
(g/day) 
Cases/Controls 
Adjusted OR [95% CI]a 
All cases Squamous 
cell 
carcinoma 
Adenocarcinoma Small cell 
carcinoma 
Non drinker 
(<0.1) 
65/57 
1.00 
24/57 
1.00 
23/57 
1.00 
10/57 
1.00 
0.1-9.9  67/91 
0.67 
[0.38-1.18] 
28/91 
0.85 
[0.39-1.84] 
21/91 
0.52 [0.24-1.10] 
11/91 
0.72 
[0.25-2.05] 
10-29.9  76/75 
0.89 
[0.50-1.58] 
23/75 
0.74 
[0.33-1.67] 
23/75 
0.72 [0.34-1.54] 
21/75 
1.54 
[0.59-4.05] 
≥30 89/68 
1.60 
[0.91-2.83] 
43/68 
2.34 
[1.10-4.96] 
23/68 
1.08 [0.51-2.30] 
11/68 
1.35 
[0.47-3.89] 
aAdjusted for age, gender, cigarette smoking in pack years (continuous), energy 
intake (calories).  
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When analyzing alcohol consumption according 
to cigarette smoking in pack years, a clear effect 
modification was observed, although the interaction 
between both variables was not statistically 
significant and the correlation was low. The highest 
increase in lung cancer risk was found for individuals 
in the higher categories of alcohol consumption (≥30 
g/day) and tobacco (≥36 PY), being the risk increased 
22.75-fold (OR = 22.75; 95% CI 7.92-65.36). 
 
Table 4: Alcohol consumption and lung cancer risk modified by 
pack-years in CAPUA Study 
aAdjusted for age, gender, energy intake (calories). 
 
 
When the association between alcohol 
consumption and lung cancer was analyzed by the 
Ile349Val polymorphism (Table 5), we found a 
statistically significant higher risk of lung cancer 
among Ile/Val heterozygotes in the highest category 
of alcohol consumption (reference category Ile/Ile 
category) (OR=2.35, 95% CI, 1.04–5.33). A higher risk 
of lung cancer was also found among Val-carriers, 
although the risk was not statistically significant 
(OR=1.89, 95% CI, 0.92–3.88). 
 
Table 5: Alcohol consumption and lung cancer risk stratified 
byAHD3 genotype in CAPUA Study 
Alcohol 
consumption 
(g/day) 
Cases/Controls  
Adjusted OR [95% CI]a 
Ile/Ile Ile/Val Val/Val Val carriers 
Non drinker 
(<0.1) 
29/21 
1.00 
29/30 
1.00 
7/6 
1.00 
36/36 
1.00 
0.1-9.9  22/32 
0.52 
[0.20-1.38] 
37/52 
0.81 
[0.36-1.84] 
8/7 
0.58 
[0.11-3.20] 
45/59 
0.77 
[0.38-1.59] 
10-29.9  31/30 
0.58 
[0.23-1.47] 
32/36 
1.20 
[0.51-2.80] 
13/9 
0.90 
[0.18-4.51] 
45/45 
1.15 
[0.55-2.41] 
≥30 36/20 
1.21 
[0.47-3.15] 
46/35 
2.35 
[1.04-5.33] 
7/13 
0.56 
[0.11-2.95] 
53/48 
1.89 
[0.92-3.88] 
aAdjusted for age, gender, cigarette smoking in pack years (continue), energy 
intake (calories).  
 
Discussion 
 In this study, we show some evidence that 
alcohol consumption at levels higher than 30 g/day 
might increase the risk of lung cancer independently 
of tobacco smoking. In view of our results, we cannot 
confirm or rule out a possible association between 
Ile349Val polymorphism in ADH3 gene and lung 
cancer risk by alcohol consumption. 
The Val variant allele results in a 2.5-fold 
reduction in the oxidation rate of alcohol to 
acetaldehyde [11]. Thus, the wild-type allele and 
wild-type genotype Ile/Ile could be related to an 
increased risk of developing lung cancer because of 
increased levels of exposure of acetaldehyde, to 
tissues. In addition, it has also been reported that after 
alcohol intake, blood acetaldehyde concentrations 
were significantly higher in individuals with the 
wild-type allele Ile compared to individuals lacking 
this allele and it has been shown that acetaldehyde 
breath levels were proportional to acetaldehyde blood 
levels [11, 44]. Therefore, exposure to a higher 
acetaldehyde concentration in the lower respiratory 
tract may play a critical role in alcohol-related 
carcinogenesis. This hypothesis is consolidated by the 
results obtained by Yang et al. [45], where Caucasians 
with wild-type genotype Ile/Ile showed higher 
pulmonary ADH activity and increased 
acetaldehyde-DNA adduct levels than individuals 
with variant genotype Val/Val. Thus, Yang et al. 
suggested that wild-type allele Ile could be 
considered a risk factor for lung cancer. 
Several studies have reported that the wild-type 
genotype of the ADH3 gene may increase the risk of 
different tumor types, including cancer of the 
oropharynx, larynx, esophagus, liver, head, and neck 
[15, 16, 46]. Other studies, however, did not find such 
an association [18, 19, 47, 48]. The number of studies in 
lung cancer is very limited. One case-control study in 
western New York did not find any association 
between the Ile349Val polymorphism in the ADH3 
gene and the risk of developing lung cancer [7]. 
Another case-control study in Japan failed to confirm 
a connection between the Ile349Val polymorphism in 
the ADH3 gene and the development of lung cancer 
[21]. The results of the present study were likewise 
unable to demonstrate an association between the 
Ile349Val polymorphism in the ADH3 gene and lung 
cancer risk.  
On the other hand, a non-significant higher risk 
of lung cancer was suggested in the highest category 
of alcohol consumption (≥30 g/day). This result is in 
agreement with the findings of Minegishi et al. [21] 
and Rohrmann et al. [49]. Before confirming an effect 
of alcohol consumption, we should take into account a 
potential residual confounding effect by cigarette 
smoking, bearing in mind the clear 
effect-modification found. We were not able to 
evaluate the effect of alcohol in nonsmokers owing to 
the insufficient sample size in our population 
subgroup. Thus, according to two reviews [12, 50], 
Alcohol 
consumption 
(g/day) 
Cases/Controls  
Adjusted OR [95% CI]a 
Never <36 ≥36 
Non drinker (<0.1) 12/23 
1.00 
10/19 
1.91 [0.61-6.01] 
43/15 
14.49 [4.94-42.50] 
0.1-9.9  6/27 
0.49 [0.15-1.64] 
14/42 
1.13 [0.40-3.22] 
47/22 
9.46 [3.28-27.30] 
10-29.9  3/19 
0.43 [0.10-1.86] 
14/30 
2.45 [0.80-7.47] 
59/26 
10.68 [3.81-29.93] 
≥30 2/17 
0.58 [0.10-3.22] 
18/34 
3.03 [1.03-8.89] 
69/17 
22.75 [7.92-65.36] 
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one meta-analysis [51], and one pooled analysis [52], 
the current evidence is insufficient to confirm an 
association between alcohol and lung cancer risk.  
Furthermore, our results showed an association 
between lung cancer and the Ile/Val genotype, 
however we cannot rule out the possibility that this 
result could be due to chance because of the multiple 
comparisons considered or by tobacco residual 
confounding. Studies carried out by Minegishi et al. 
[21] and Freudenheim et al. [7] did not find a clear 
association between Ile349Val polymorphism in 
ADH3 gene and lung cancer risk by alcohol 
consumption. These findings should be investigated 
in more detail in further studies, considering larger 
sample sizes and alternative genotyping techniques. 
The main strengths of our study are the high 
number of eligible cases, the reasonably large sample 
size from a homogeneous population of comparable 
descent, and the fact that all of our control subjects 
were under Hardy–Weinberg equilibrium. 
Furthermore, the whole of our cases were 
pathologically confirmed with the exception of 6 
treated as lung cancer without need of pathologic 
confirmation, and high quality control for genotyping 
was applied. Our estimates for alcohol consumption 
were adjusted for smoking consumption and several 
other factors, such as energy and vegetable intake, 
were estimated by validated FFQ. Our study may also 
have some limitations. The observational design of 
the study and the use of hospital-based subjects may 
make our results more susceptible to bias (e.g., recall 
bias in collecting information on smoking 
retrospectively; underreporting of alcohol 
consumption; or selection bias). In order to minimize 
the potential selection bias, controls were selected 
among patients admitted with diagnoses in principle 
unrelated to exposures of interest. Even so, Campbell 
et al (2005) stated that European populations might 
show different levels of genetic substructure that 
could lead to false-positive associations as the result 
of population stratification [53]. In our study we 
controlled for that possibility with the inclusion of 
individuals from the same European ancestry 
(Caucasians). Regarding a potential misreporting of 
alcohol intake among cases and controls, if any, it 
should be non-differential and our effect estimates for 
alcohol consumption should be even stronger. The 
lack of information on alcohol consumption and 
dietary intake on one quarter of the study population 
was not related to the outcome and missing values 
were randomly distributed. However, it had reduced 
statistical power and the accuracy of estimates. 
Finally, the quite small sample size of some 
subgroups when analysis was stratified has prevented 
us from scoring statistically significance in them. 
This work represents one of the few studies in 
which the effect of alcohol consumption on lung 
cancer risk was investigated beyond the tobacco 
smoking effect, and taking into account the Ile349Val 
polymorphism. To confirm or disregard our findings 
for the Ile349Val polymorphism, future studies 
should evaluate the effect of alcohol on lung cancer 
risk, undertaking assays of ADH activity and, if 
possible, exploring other polymorphisms potentially 
implicated in alcohol metabolism.  
Conclusions 
High alcohol consumption might have a slight 
effect on lung cancer development as well as a 
synergistic effect with tobacco. No clear association 
was found between alcohol consumption and lung 
cancer according to the Ile349Val polymorphism in 
ADH3 gene. 
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